CD3 Bispecific Antibodies With Tunable Affinity for Lower Cytokine Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD3-based bispecific antibodies for T-cell activation in cancer therapy exhibit high toxicity due to non-specific T-cell activation and cytokine release syndrome, limiting their therapeutic potential.
Innovation Solution
Development of a family of anti-CD3 antibodies with tunable binding affinities (KD ranging from 10−6 to 10−11) that minimize cytokine release while maintaining effective tumor cell lysis, including bispecific antibodies with specific binding to CD3 and tumor-associated antigens like BCMA, using optimized CDR sequences for CD3 and light chain variable regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD3-based bispecific antibodies are used to activate T cells for tumor cell lysis, then antitumor efficacy is improved, but toxicity and cytokine release syndrome increase
Solution Approach 1:
The patent applies parameter changes by systematically varying the affinity of anti-CD3 antibodies across a defined range (10^-6 to 10^-11 M) to optimize the balance between T cell activation efficacy and toxicity reduction. This allows selection of antibodies with affinity parameters that achieve therapeutic effect while minimizing harmful cytokine release
Solution Approach 2:
The patent implements dynamics by creating a family of antibodies with tunable, adjustable affinity characteristics rather than a single fixed affinity. This dynamic range enables adaptation to different therapeutic needs and patient conditions, allowing optimization of the efficacy-toxicity ratio
2Productivity
If high affinity anti-CD3 antibodies are used to activate T cells, then T cell activation is enhanced, but non-specific activation and toxicity increase
Solution Approach 1:
The patent changes the affinity parameter of anti-CD3 antibodies from uniformly high affinity to a distributed range of affinities (10^-6 to 10^-11 M). This parameter variation allows identification of optimal affinity values that activate T cells effectively against tumor cells while reducing non-specific activation of normal cells
3Ease of operation
If existing anti-CD3 antibodies with affinity 1-50 nM KD are used, then T cell recruitment is achieved, but therapeutic optimization is limited
Solution Approach 1:
The patent extends the affinity parameter range from the conventional 1-50 nM KD to a broader spectrum (10^-6 to 10^-11 M), providing additional therapeutic options. This parameter expansion enables fine-tuning of antibody-CD3 interactions to optimize therapeutic outcomes for different cancer types and patient responses
Solution Approach 2:
The patent creates a universal antibody family that can function across multiple affinity ranges, making the system adaptable to various therapeutic scenarios. The same platform can be tuned for different indications, patient populations, and desired activation thresholds, enhancing versatility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies reduce toxicity and cytokine release, optimizing tumor cell lysis by selectively activating CD3+ T cells, thereby enhancing therapeutic efficacy with reduced side effects.
Implementation Method 1
The antibodies bind to and activate signaling through CD3, e.g. activation of CD3+ T cells
Data Source
AI summary
The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.